Results
Between 27/03/2018 and 25/03/2020, 66 participants were screened for eligibility. Of these participants 39 were screen failures and 27 participants were randomly assigned to subcutaneous liraglutide 1.8 mg once daily or placebo for 6 months. Twenty-seven of the target 58 participants were therefore randomised to this trial. Of the participants randomised two were lost to follow-up (